Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26850676 | 1.00 | DDB1 (0.48) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21997642 | 0.93 | CRBN (0.48) | DDB1CRBNIKZF3 | |
| SCHEMBL26635128 | 0.91 | CRBN (0.48) | DDB1CRBNIKZF3 | |
| SCHEMBL26635052 | 0.89 | DDB1 (0.51) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26850661 | 0.85 | GPR119 (0.42) | DDB1CRBN | |
| SCHEMBL31003947 | 0.85 | GPR119 (0.42) | DDB1CRBN | |
| SCHEMBL21070862 | 0.84 | CRBN (0.52) | DDB1CRBNIKZF3 | |
| SCHEMBL31701106 | 0.84 | CRBN (0.52) | DDB1CRBNIKZF3 | |
| SCHEMBL26634965 | 0.84 | CRBN (0.52) | DDB1CRBNIKZF3 | |
| SCHEMBL26634996 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885IKZF3 395/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885IKZF3 395/4885 |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885IKZF3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.